/
CNSP
$4.15+$0.17 (+4.27%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$5.8M
1M shares
52-week range
$1.90 – $12.36
22% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
574.92%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-1763995.85
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $2.0K | $11.1K | $13.1K | $11.8K | $4.1K | $3.3K | $0 |
| Gross profit | $0 | −$2.0K | −$11.1K | −$13.1K | −$11.8K | −$4.1K | −$3.3K | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $21.3K | $1.9M | $5.1M | $9.8M | $9.3M | $14.1M | $9.3M | $9.8M |
| Operating income | −$881.8K | −$3.8M | −$9.5M | −$14.5M | −$14.9M | −$18.9M | −$14.9M | −$16.0M |
| EBITDA | −$6.5M | −$3.8M | −$9.4M | −$14.5M | −$15.3M | −$18.8M | −$14.8M | −$15.8M |
| Net income | −$7.4M | −$3.9M | −$9.5M | −$14.5M | −$15.3M | −$18.9M | −$14.9M | −$15.9M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -404415.00 | -212121.00 | -512208.00 | -495027.00 | -336499.00 | -150114.00 | -466.44 | -35.75 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $41M | $-1.65 | $-1.65–$-1.65 | 1 |
| 2027 | $50M | $-1.66 | $-1.66–$-1.66 | 1 |
| 2028 | $76M | $-1.88 | $-1.88–$-1.88 | 1 |
| 2029 | $0 | $-1.99 | $-1.99–$-1.99 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$7.64
Price
$4.15
Implied upside
+84%
Peer comparison
CNS Pharmaceuticals, Inc. Common Stock
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
www.cnspharma.com- Employees
- 8
- IPO / List date
- Nov 8, 2019
- HQ
- HOUSTON, TX
Held by traders on TradeandTell
No one on the platform currently holds CNSP.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CNSP as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-07-22 | 1-for-12reverse |
| 2025-02-21 | 1-for-50reverse |
| 2024-06-05 | 1-for-50reverse |
| 2022-11-29 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded CNSP yet.
